199 related articles for article (PubMed ID: 31171773)
1. PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2019 Jun; 10(1):2484. PubMed ID: 31171773
[TBL] [Abstract][Full Text] [Related]
2. PRL3-zumab, a first-in-class humanized antibody for cancer therapy.
Thura M; Al-Aidaroos AQO; Yong WP; Kono K; Gupta A; Lin YB; Mimura K; Thiery JP; Goh BC; Tan P; Soo R; Hong CW; Wang L; Lin SJ; Chen E; Rha SY; Chung HC; Li J; Nandi S; Yuen HF; Zhang SD; Guan YK; So J; Zeng Q
JCI Insight; 2016 Jun; 1(9):e87607. PubMed ID: 27699276
[TBL] [Abstract][Full Text] [Related]
3. A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE; Ooi M; Lee SC; Sundar R; Heong V; Yong WP; Ng CH; Wong A; Lim JSJ; Tan DSP; Soo R; Tan JTC; Yang S; Thura M; Al-Aidaroos AQ; Chng WJ; Zeng Q; Goh BC
Target Oncol; 2023 May; 18(3):391-402. PubMed ID: 37060431
[TBL] [Abstract][Full Text] [Related]
4. PRL3 induces polypoid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse.
Thura M; Ye Z; Al-Aidaroos AQ; Xiong Q; Ong JY; Gupta A; Li J; Guo K; Ang KH; Zeng Q
Commun Biol; 2021 Jul; 4(1):923. PubMed ID: 34326464
[TBL] [Abstract][Full Text] [Related]
5. Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP; Thura M; Gupta A; Tan SH; Kuan KKY; Ang KH; Merchant K; Chang KTE; Yon HY; Chen Y; Cheng MHW; Mahadev A; Ng MCH; Seng MS; Iyer P; Chia PL; Soh SY; Zeng Q
Mol Ther Oncolytics; 2023 Sep; 30():153-166. PubMed ID: 37674627
[TBL] [Abstract][Full Text] [Related]
6. PRL3 as a therapeutic target for novel cancer immunotherapy in multiple cancer types.
Chia PL; Ang KH; Thura M; Zeng Q
Theranostics; 2023; 13(6):1876-1891. PubMed ID: 37064866
[TBL] [Abstract][Full Text] [Related]
7. Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis.
Zhang T; Liu L; Lai W; Zeng Y; Xu H; Lan Q; Su P; Chu Z
Oncol Rep; 2019 May; 41(5):2790-2802. PubMed ID: 30864736
[TBL] [Abstract][Full Text] [Related]
8. slan
Vermi W; Micheletti A; Finotti G; Tecchio C; Calzetti F; Costa S; Bugatti M; Calza S; Agostinelli C; Pileri S; Balzarini P; Tucci A; Rossi G; Furlani L; Todeschini G; Zamò A; Facchetti F; Lorenzi L; Lonardi S; Cassatella MA
Cancer Res; 2018 Jul; 78(13):3544-3559. PubMed ID: 29748373
[TBL] [Abstract][Full Text] [Related]
9. CD24 targeting bi-specific antibody that simultaneously stimulates NKG2D enhances the efficacy of cancer immunotherapy.
Han Y; Sun F; Zhang X; Wang T; Jiang J; Cai J; Gao Q; Hezam K; Liu Y; Xie J; Wang M; Zhang J
J Cancer Res Clin Oncol; 2019 May; 145(5):1179-1190. PubMed ID: 30778749
[TBL] [Abstract][Full Text] [Related]
10. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
11. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
12. PRL3 promotes cell invasion and proliferation by down-regulation of Csk leading to Src activation.
Liang F; Liang J; Wang WQ; Sun JP; Udho E; Zhang ZY
J Biol Chem; 2007 Feb; 282(8):5413-9. PubMed ID: 17192274
[TBL] [Abstract][Full Text] [Related]
13. RNAi‑mediated knockdown of PRL‑3 inhibits cell invasion and downregulates ERK 1/2 expression in the human gastric cancer cell line, SGC‑7901.
Cao Y; Tu Y; Mei J; Li Z; Jie Z; Xu S; Xu L; Wang S; Xiong Y
Mol Med Rep; 2013 Jun; 7(6):1805-11. PubMed ID: 23589069
[TBL] [Abstract][Full Text] [Related]
14. Role of ADAM17 as a regulatory checkpoint of CD16A in NK cells and as a potential target for cancer immunotherapy.
Wu J; Mishra HK; Walcheck B
J Leukoc Biol; 2019 Jun; 105(6):1297-1303. PubMed ID: 30786043
[TBL] [Abstract][Full Text] [Related]
15. Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors.
Bruckheimer EM; Fazenbaker CA; Gallagher S; Mulgrew K; Fuhrmann S; Coffman KT; Walsh W; Ready S; Cook K; Damschroder M; Kinch M; Kiener PA; Woods R; Gao C; Dall'Acqua W; Wu H; Coats S
Neoplasia; 2009 Jun; 11(6):509-17, 2 p following 517. PubMed ID: 19484140
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab.
Kurdi AT; Glavey SV; Bezman NA; Jhatakia A; Guerriero JL; Manier S; Moschetta M; Mishima Y; Roccaro A; Detappe A; Liu CJ; Sacco A; Huynh D; Tai YT; Robbins MD; Azzi J; Ghobrial IM
Mol Cancer Ther; 2018 Jul; 17(7):1454-1463. PubMed ID: 29654064
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201).
El-Sahwi K; Bellone S; Cocco E; Casagrande F; Bellone M; Abu-Khalaf M; Buza N; Tavassoli FA; Hui P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
Mol Cancer Ther; 2010 Jan; 9(1):57-66. PubMed ID: 20053761
[TBL] [Abstract][Full Text] [Related]
18. Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein.
Thura M; Al-Aidaroos AQ; Gupta A; Chee CE; Lee SC; Hui KM; Li J; Guan YK; Yong WP; So J; Chng WJ; Ng CH; Zhou J; Wang LZ; Yuen JSP; Ho HSS; Yi SM; Chiong E; Choo SP; Ngeow J; Ng MCH; Chua C; Yeo ESA; Tan IBH; Sng JXE; Tan NYZ; Thiery JP; Goh BC; Zeng Q
Nat Commun; 2021 Nov; 12(1):6431. PubMed ID: 34728638
[No Abstract] [Full Text] [Related]
19. PRL3 enhances T-cell acute lymphoblastic leukemia growth through suppressing T-cell signaling pathways and apoptosis.
Garcia EG; Veloso A; Oliveira ML; Allen JR; Loontiens S; Brunson D; Do D; Yan C; Morris R; Iyer S; Garcia SP; Iftimia N; Van Loocke W; Matthijssens F; McCarthy K; Barata JT; Speleman F; Taghon T; Gutierrez A; Van Vlierberghe P; Haas W; Blackburn JS; Langenau DM
Leukemia; 2021 Mar; 35(3):679-690. PubMed ID: 32606318
[TBL] [Abstract][Full Text] [Related]
20. Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy.
Hubert P; Heitzmann A; Viel S; Nicolas A; Sastre-Garau X; Oppezzo P; Pritsch O; Osinaga E; Amigorena S
Cancer Res; 2011 Aug; 71(15):5134-43. PubMed ID: 21697279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
